37 related articles for article (PubMed ID: 38434771)
1. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
[TBL] [Abstract][Full Text] [Related]
3. Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC-RELANCE/LACOG 0118.
Cordeiro de Lima VC; Gelatti A; Moura JFP; Fares AF; de Castro G; Mathias C; Terra RM; Werutsky G; Corassa M; Araújo LHL; Cronenberger E; Fujiki FK; Reichow S; da Silva AVT; Reis TV; Padoan MLA; Pacheco P; Yamamura R; Kawamura C; Mascarenhas E; de Jesus RG; Gössling G; Baldotto C
JTO Clin Res Rep; 2024 Mar; 5(3):100646. PubMed ID: 38434771
[TBL] [Abstract][Full Text] [Related]
4. Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort.
Cordeiro de Lima VC; Baldotto CS; Barrios CH; Sobrinho EM; Zukin M; Mathias C; Zaffaroni F; Nery RC; Madeira G; Amadio AV; Coelho JC; Geib G; Simões MF; Castro G
J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241276
[TBL] [Abstract][Full Text] [Related]
5. Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
Cronemberger E; Baldotto C; Marinho F; De Marchi P; Araújo LH; Franke F; Salles P; Calabrich A; Almeida T; Custodio MG; Maria AS; Pereira MH; Castro G
Clinics (Sao Paulo); 2020; 75():e1777. PubMed ID: 33084767
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
[TBL] [Abstract][Full Text] [Related]
7. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study.
Jazieh AR; Onal HC; Tan DSW; Soo RA; Prabhash K; Kumar A; Huggenberger R; Robb S; Cho BC
J Thorac Oncol; 2021 Oct; 16(10):1733-1744. PubMed ID: 34051381
[TBL] [Abstract][Full Text] [Related]
9. Non-Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417).
Coelho JC; de Souza Carvalho G; Chaves F; de Marchi P; de Castro G; Baldotto C; Mascarenhas E; Pacheco P; Gomes R; Werutsky G; Araujo LH
JCO Glob Oncol; 2022 Mar; 8():e2100333. PubMed ID: 35467932
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM; Spicer J; Lu S; Provencio M; Mitsudomi T; Awad MM; Felip E; Broderick SR; Brahmer JR; Swanson SJ; Kerr K; Wang C; Ciuleanu TE; Saylors GB; Tanaka F; Ito H; Chen KN; Liberman M; Vokes EE; Taube JM; Dorange C; Cai J; Fiore J; Jarkowski A; Balli D; Sausen M; Pandya D; Calvet CY; Girard N;
N Engl J Med; 2022 May; 386(21):1973-1985. PubMed ID: 35403841
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Spigel DR; Faivre-Finn C; Gray JE; Vicente D; Planchard D; Paz-Ares L; Vansteenkiste JF; Garassino MC; Hui R; Quantin X; Rimner A; Wu YL; Özgüroğlu M; Lee KH; Kato T; de Wit M; Kurata T; Reck M; Cho BC; Senan S; Naidoo J; Mann H; Newton M; Thiyagarajah P; Antonia SJ
J Clin Oncol; 2022 Apr; 40(12):1301-1311. PubMed ID: 35108059
[TBL] [Abstract][Full Text] [Related]
12. Demographic and Clinical Outcomes of Brazilian Patients With Stage III or IV Non-Small-Cell Lung Cancer: Real-World Evidence Study on the Basis of Deterministic Linkage Approach.
Ferreira CG; Abadi MD; de Mendonça Batista P; Serra FB; Peixoto RB; Okumura LM; Cerqueira ER
JCO Glob Oncol; 2021 Sep; 7():1454-1461. PubMed ID: 34609902
[TBL] [Abstract][Full Text] [Related]
13. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
Ronden MI; Bahce I; Hashemi SMS; Dickhoff C; de Haan PF; Becker A; Spoelstra FOB; Dahele MR; Ali R; Tiemessen MA; Tarasevych S; Maassen van den Brink K; Haasbeek CJA; Daniels JMA; van Laren M; Verbakel WFAR; Senan S
Lung Cancer; 2021 Feb; 152():149-156. PubMed ID: 33418430
[TBL] [Abstract][Full Text] [Related]
15. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
Rice SR; Vyfhuis MAL; Scilla KA; Burrows WM; Bhooshan N; Suntharalingam M; Edelman MJ; Feliciano J; Badiyan SN; Simone CB; Bentzen SM; Feigenberg SJ; Mohindra P
Clin Lung Cancer; 2020 May; 21(3):e130-e141. PubMed ID: 31708388
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
